Clinical oncology (Royal College of Radiologists (Great Britain)) · 2025
A Comparative Study of Initiated Chemotherapy Versus Initiated Surgery Combined with Primary-Radiotherapy in Locoregionally Advanced Hypopharyngeal Carcinoma.
СтатьяСравнительное исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhao D-W, Jiang H-Y, Fan W-J, Meng L-L, Qu Y-J, Ren G-B, Guo X-F, Liu C-L, Cai B-N, Wang P-G, Ma L
Аннотация
BACKGROUND: Laryngeal preservation is a pivotal treatment goal in managing locally advanced hypopharyngeal carcinoma (LAHPC). This study compares the outcomes of induction chemotherapy followed by concurrent chemoradiotherapy (IcRT) and surgery followed by radiotherapy or concurrent chemoradiotherapy (SurRT) in patients with LAHPC.
METHODS: This study included 182 patients with LAHPC treated with either IcRT (n = 137) or SurRT (n = 45). Survival with a functional larynx (SFL), overall survival (OS), progression-free survival (PFS), local failure-free survival (LFFS), locoregional failure-free survival (LRFFS), and distant metastasis-free survival (DMFS) were analyzed. Propensity score matching (PSM) was performed to balance baseline characteristics between the two treatment groups.
RESULTS: The IcRT group demonstrated significantly superior 5-yr SFL compared to the SurRT group (50.4% vs. 30.5%, HR 2.38, 95% CI 1.40-4.03, P < 0.001). However, there were no significant differences between the two groups in 5-yr OS (55.2% vs. 56.8%, HR 0.80, P = 0.41), PFS (48.5% vs. 45.7%, HR 0.99, P = 0.99), LFFS (55.1% vs. 57.7%, HR 0.86, P = 0.57), or DMFS (50.2% vs. 42.8%, HR 1.02, P = 0.90), in both pre- and post-PSM analyses. The IcRT group exhibited greater radiation-related toxicities but achieved better local control and distant metastasis rates, while the SurRT group had a lower rate of regional recurrence. T classification and clinical stage were identified as independent prognostic factors for survival outcomes.
CONCLUSIONS: IcRT may offer enhanced laryngeal preservation compared to SurRT in select patients, albeit with higher acute toxicities. Treatment decisions should prioritize both oncologic outcomes and patient tolerance.
METHODS: This study included 182 patients with LAHPC treated with either IcRT (n = 137) or SurRT (n = 45). Survival with a functional larynx (SFL), overall survival (OS), progression-free survival (PFS), local failure-free survival (LFFS), locoregional failure-free survival (LRFFS), and distant metastasis-free survival (DMFS) were analyzed. Propensity score matching (PSM) was performed to balance baseline characteristics between the two treatment groups.
RESULTS: The IcRT group demonstrated significantly superior 5-yr SFL compared to the SurRT group (50.4% vs. 30.5%, HR 2.38, 95% CI 1.40-4.03, P < 0.001). However, there were no significant differences between the two groups in 5-yr OS (55.2% vs. 56.8%, HR 0.80, P = 0.41), PFS (48.5% vs. 45.7%, HR 0.99, P = 0.99), LFFS (55.1% vs. 57.7%, HR 0.86, P = 0.57), or DMFS (50.2% vs. 42.8%, HR 1.02, P = 0.90), in both pre- and post-PSM analyses. The IcRT group exhibited greater radiation-related toxicities but achieved better local control and distant metastasis rates, while the SurRT group had a lower rate of regional recurrence. T classification and clinical stage were identified as independent prognostic factors for survival outcomes.
CONCLUSIONS: IcRT may offer enhanced laryngeal preservation compared to SurRT in select patients, albeit with higher acute toxicities. Treatment decisions should prioritize both oncologic outcomes and patient tolerance.